Regorafenib

Regorafenib (brand name Stivarga) is an oral, multi-kinase inhibitor used to treat advanced, treatment-resistant metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (liver cancer). It works by blocking kinases that promote tumor growth, angiogenesis, and tumor microenvironment maintenance. Common side effects include hand-foot skin reaction (HFSR), fatigue, high blood pressure, diarrhea, and infection.